YL-15293 for Solid Tumors

The Tisch Cancer Institute Mount Sinai Health System Icahn School of Medicine at Mount Sinai, New York, NY
Solid TumorsYL-15293 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug, YY-15293, to see if it is safe and effective in treating patients with advanced solid tumors (cancer that has spread) with a KRAS G12C mutation.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Throughout the study for approximately 2 years

Year 2
Disease control rate, DCR
Overall survival, OS
Progression free survival, PFS
The overall response rate (ORR)

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

55 Total Participants · 1 Treatment Group

Primary Treatment: YL-15293 · No Placebo Group · Phase 1 & 2

Experimental Group · 1 Intervention: YL-15293 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: throughout the study for approximately 2 years

Who is running the clinical trial?

Shanghai YingLi Pharmaceutical Co. Ltd.Lead Sponsor
15 Previous Clinical Trials
1,173 Total Patients Enrolled
Yingli Pharma US, IncUNKNOWN
1 Previous Clinical Trials
54 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are there still openings for enrolment in this trial?

"Confirmed. Clinicaltrials.gov reports that this medical experiment was initially announced on November 9th 2021 and has been most recently updated on the 11th of the same month, indicating it is actively seeking participants." - Anonymous Online Contributor

Unverified Answer

What is the current intake quota for this clinical trial?

"The sponsor, Shanghai YingLi Pharmaceutical Co. Ltd., must enroll 55 qualified participants across multiple sites; including Oncology Consultants in Houston and Innovative Clinical Research Institute in Whittier." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.